Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies
Simple Summary Apart from genetic changes, cancer is characterized by epigenetic alterations, which indicate modifications in the DNA (such as DNA methylation) and histones (such as methylation and acetylation), as well as gene expression regulation by non-coding (nc)RNAs. These changes can be used...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | English |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/62690 |
| _version_ | 1793400064266207232 |
|---|---|
| author | Palanca-Ballester, C. (Cora) Rodríguez-Casanova, A. (Aitor) Torres, S. (Susana) Calabuig-Fariñas, S. (Silvia) Expósito, F. (Francisco) Serrano-Tejero, D. (Diego) Redín, E. (Esther) Valencia, K. (Karmele) Jantus-Lewintre, E. (Eloisa) Diaz-Lagares, A. (Ángel) Montuenga-Badia, L.M. (Luis M.) Sandoval, J. (Juan) Calvo-González, A. (Alfonso) |
| author_facet | Palanca-Ballester, C. (Cora) Rodríguez-Casanova, A. (Aitor) Torres, S. (Susana) Calabuig-Fariñas, S. (Silvia) Expósito, F. (Francisco) Serrano-Tejero, D. (Diego) Redín, E. (Esther) Valencia, K. (Karmele) Jantus-Lewintre, E. (Eloisa) Diaz-Lagares, A. (Ángel) Montuenga-Badia, L.M. (Luis M.) Sandoval, J. (Juan) Calvo-González, A. (Alfonso) |
| author_sort | Palanca-Ballester, C. (Cora) |
| collection | DSpace |
| description | Simple Summary Apart from genetic changes, cancer is characterized by epigenetic alterations, which indicate modifications in the DNA (such as DNA methylation) and histones (such as methylation and acetylation), as well as gene expression regulation by non-coding (nc)RNAs. These changes can be used in biological fluids (liquid biopsies) for diagnosis, prognosis and prediction of cancer drug response. Although these alterations are not widely used as biomarkers in the clinical practice yet, increasing number of commercial kits and clinical trials are expected to prove that epigenetic changes are able to offer valuable information for cancer patients. Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-62690 |
| institution | Universidad de Navarra |
| language | English |
| publishDate | 2022 |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-626902023-02-17T13:52:12Z Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies Palanca-Ballester, C. (Cora) Rodríguez-Casanova, A. (Aitor) Torres, S. (Susana) Calabuig-Fariñas, S. (Silvia) Expósito, F. (Francisco) Serrano-Tejero, D. (Diego) Redín, E. (Esther) Valencia, K. (Karmele) Jantus-Lewintre, E. (Eloisa) Diaz-Lagares, A. (Ángel) Montuenga-Badia, L.M. (Luis M.) Sandoval, J. (Juan) Calvo-González, A. (Alfonso) Epigenetic biomarkers Cancer DNA methylation Micro-RNAs Simple Summary Apart from genetic changes, cancer is characterized by epigenetic alterations, which indicate modifications in the DNA (such as DNA methylation) and histones (such as methylation and acetylation), as well as gene expression regulation by non-coding (nc)RNAs. These changes can be used in biological fluids (liquid biopsies) for diagnosis, prognosis and prediction of cancer drug response. Although these alterations are not widely used as biomarkers in the clinical practice yet, increasing number of commercial kits and clinical trials are expected to prove that epigenetic changes are able to offer valuable information for cancer patients. Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). 2022-01-10T10:48:29Z 2022-01-10T10:48:29Z 2021 info:eu-repo/semantics/article https://hdl.handle.net/10171/62690 en info:eu-repo/semantics/openAccess application/pdf |
| spellingShingle | Epigenetic biomarkers Cancer DNA methylation Micro-RNAs Palanca-Ballester, C. (Cora) Rodríguez-Casanova, A. (Aitor) Torres, S. (Susana) Calabuig-Fariñas, S. (Silvia) Expósito, F. (Francisco) Serrano-Tejero, D. (Diego) Redín, E. (Esther) Valencia, K. (Karmele) Jantus-Lewintre, E. (Eloisa) Diaz-Lagares, A. (Ángel) Montuenga-Badia, L.M. (Luis M.) Sandoval, J. (Juan) Calvo-González, A. (Alfonso) Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title | Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title_full | Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title_fullStr | Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title_full_unstemmed | Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title_short | Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| title_sort | cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies |
| topic | Epigenetic biomarkers Cancer DNA methylation Micro-RNAs |
| url | https://hdl.handle.net/10171/62690 |
| work_keys_str_mv | AT palancaballesterccora cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT rodriguezcasanovaaaitor cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT torresssusana cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT calabuigfarinasssilvia cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT expositoffrancisco cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT serranotejeroddiego cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT redineesther cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT valenciakkarmele cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT jantuslewintreeeloisa cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT diazlagaresaangel cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT montuengabadialmluism cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT sandovaljjuan cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies AT calvogonzalezaalfonso cancerepigeneticbiomarkersinliquidbiopsyforhighincidencemalignancies |